Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with

Margo B Gerke1, Angelo Marra2, Michelle Jayaraj1

  • 1Emory University School of Medicine, Atlanta, GA 30322, USA.

The Oncologist
|July 11, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<sup>68</sup>Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data.

European journal of nuclear medicine and molecular imaging·2026
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

<sup>18</sup>F-Fluciclovine or <sup>68</sup>Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.

Radiology·2026
Same author

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Bladder activity of different PSMA PET radioligands and impact of furosemide.

American journal of nuclear medicine and molecular imaging·2026
Same author

Response to the Comment on "Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity By Immunohistochemistry."

Clinical nuclear medicine·2026

A new risk score combining body composition and inflammatory markers helps predict outcomes for patients with metastatic castration-resistant prostate cancer receiving Lutetium-177(177Lu)-PSMA-617 therapy. This tool aids in stratifying patients for improved treatment planning.

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Prognostic Biomarkers

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) treatment with Lutetium-177(177Lu)-PSMA-617 shows survival benefits, but patient outcomes vary significantly.
  • Standardized tools for risk stratification in patients undergoing 177Lu-PSMA-617 therapy are currently lacking, hindering personalized treatment approaches.

Purpose of the Study:

  • To develop and validate a novel risk stratification tool for patients with mCRPC treated with 177Lu-PSMA-617.
  • To identify key predictors of progression-free survival (PFS) and overall survival (OS) in this patient cohort.

Main Methods:

  • Retrospective analysis of 163 mCRPC patients treated with 177Lu-PSMA-617.
  • Development of four prognostic models using Cox proportional hazards models and best-subset variable selection.
Keywords:
BiomarkerBody CompositionInflammationLutetium-177–PSMA-617Risk scoring systemmetastatic castration-resistant prostate cancerradioligand therapytheranostics

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

  • Integration of models into a composite score incorporating body composition and inflammatory biomarkers.

    • Main Results:

    • Body mass index (BMI) decline during treatment correlated with shorter PFS and OS.
    • Higher subcutaneous adipose tissue index (SATI)/skeletal muscle index (SMI) was linked to improved OS, while higher visceral adipose tissue index (VATI)/SATI was associated with worse OS.
    • A composite risk score integrating body composition (VATI/SATI, SMI, adiposity) and inflammatory biomarkers demonstrated strong prognostic value, effectively stratifying patients by PFS and OS (C-index = 0.732).

    Conclusions:

    • A novel risk score incorporating body composition and inflammatory biomarkers provides significant prognostic value for patients receiving 177Lu-PSMA-617.
    • This tool can aid in stratifying mCRPC patients, potentially guiding treatment decisions and improving patient outcomes.